Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 7 recruiting now early-phase tilt small index

ER+ Breast Cancer: early-phase trial registry

7 of 9 indexed ER+ Breast Cancer trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #1,916 of 28,707 conditions by registered trial count.

9 US clinical trials · 7 currently recruiting · #1,916 of 28,707 conditions by registered trial count

ER+ Breast Cancer: 9 US clinical trials tracked, 7 recruiting.

ER+ Breast Cancer is the subject of 9 registered US clinical trials on ClinicalTrials.gov, 7 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 8 in Phase 1-2 (earlier-stage). The most active sponsor is Memorial Sloan Kettering Cancer Center, running 2 of these trials.

Enrollment posture brief

Registry condition er-breast-cancer

OPEN 7 | RECR 78% | LATE 0 | EARLY 8 | RANK #1916 | SPON 2

Nearest open-share peer: Advanced Colorectal Carcinoma (78% recruiting · 9 trials)

ER+ Breast Cancer (this)78%Acute Lymphoblastic Leukemia55.6%Acute Respiratory Distress S55.6%Acute Otitis Media22.2%Acute Heart Failure11.1%
Open-enrollment share among volume-matched conditions near ER+ Breast Cancer

ER+ Breast Cancer lists 7 open slots (78% of 9 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for ER+ Breast Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. ER+ Breast Cancer is recruiting above its size-band peers.

    7 of 9 indexed trials (77.8%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates ER+ Breast Cancer research.

    Memorial Sloan Kettering Cancer Center accounts for 2 of 9 trials (22.2%). 8 distinct sponsors appear on at least one study for this condition label.

  3. Typical ER+ Breast Cancer enrolment sits around 85 participants.

    Median target enrolment is 85 among the 9 trials that report a genuine target (sentinel values excluded). 5 of those (55.6%) plan for fewer than 100 participants.

  4. ER+ Breast Cancer research is mostly interventional.

    9 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 15Phase 23

Open and recent trials

9 total, page 1 of 1

Phase Distribution

PhaseTrial count
Phase 1 5
Phase 2 3

Named interventions

Most-linked intervention names on ER+ Breast Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

BBI-825 Drug
1 trials
BBI-355 Drug
1 trials
FES Pet/ct Diagnostic test
1 trials
RYZ101 Drug
1 trials
Erlotinib Drug
1 trials
Neoadjuvant endocrine therapy Drug
1 trials
ETX-19477 Drug
1 trials
Futibatinib Drug
1 trials

US sites by state

Facility locations filed on ER+ Breast Cancer trials. A trial with sites in several states counts in each.

New York 6 trials
Texas 4 trials
Pennsylvania 4 trials
Massachusetts 4 trials
Florida 4 trials
Michigan 3 trials
Wisconsin 2 trials
Washington 2 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this ER+ Breast Cancer page

9 registered trials, 7 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This ER+ Breast Cancer condition card totals 9 registered trials; most-linked intervention BBI-825; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.